|
|
 |
|
Viewing report
|
|
|
|
Baxter International Inc.: PharmaVitae Profile
Datamonitor, Dec 2010, Pages: 79
Introduction
This analysis examines the historical and forecast performance for Baxter in the prescription pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs.
Features and benefits
- Gain insight into Baxter's strategic outlook across the next 6 years
- Analyze company sales forecasts by product, therapy area, lifecycle stage, geography, molecule type and source
Highlights
- Strategic insight into the prospects for Baxter over the next six years.
- Picking out key strengths, weaknesses, opportunities and threats and evaluating the company's prescription pharmaceuticals outlook using a variety of cuts of the historical and forecast sales.
Your key questions answered
- Benchmark Baxter's performance against key rivals in the prescription pharmaceutical sector
- Assess the importance of Baxter's 'wild card' Gammagard for Alzheimer's disease, currently in Phase III trials, in driving sales growth out to 2015
|
|
|
|
